Mingteng International vs WORK Medical Technology
MTEN and WOK side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MTEN and WOK compare
Mingteng International grew revenue faster over the last twelve months (15.3% versus −14.4% for WORK Medical Technology).
WORK Medical Technology keeps more of each dollar of sales as profit, with a net margin of −10.9% compared with −15.3% at Mingteng International.
Mingteng International scores higher on the StockData Score (6 against 5 for WORK Medical Technology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MTEN | WOK |
|---|---|---|
| Size and price | ||
| Share price | $0.350 | $1.20 |
| Change, 1 year | −99.9% | −100.0% |
| Beta (5Y) | 2.52 | 1.16 |
| Employees | 31 | 46 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 15.3% (better) | −14.4% |
| Profitability | ||
| Gross margin | 22.5% | 23.8% (better) |
| Operating margin | −3.6% | – |
| Net margin | −15.3% | −10.9% (better) |
| FCF margin | −9.5% | 49.9% (better) |
| Return on equity | −11.7% | −5.0% (better) |
| Return on invested capital | −2.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.22 (better) |
| Net debt / EBITDA | – | 9.70 |
| Interest coverage | −10.9× | – |
| Current ratio | 1.19 | 1.37 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Ownership | ||
| Held by institutions | – | 0.00% |
| Held by insiders | 27.7% | 0.22% |
| Insider net buying, 12 months | $380K (better) | −$178K |
| Short interest, % of float | 1.4% | 0.13% |
Go deeper
- MTEN stock overview
- MTEN income statement
- MTEN valuation and score
- WOK stock overview
- WOK income statement
- WOK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.